血管內(nèi)皮生長因子B(VEGFB)重組蛋白
Recombinant Vascular Endothelial Growth Factor B (VEGFB)
VEGF-B; VEGFL; VRF; VEGF-Related Factor
- 編號RPA144Ra01
- 物種Rattus norvegicus (Rat,大鼠) 相同的名稱,不同的物種。
- 來源原核表達(dá)
- 宿主E.coli
- 內(nèi)毒素水平<1.0EU/µg(LAL法測定)
- 亞細(xì)胞定位分泌
- 預(yù)測分子量16.8kDa
- 實際分子量17kDa(差異分析請參閱說明書)
- 片段與標(biāo)簽Ala21~Ser137 with N-terminal His Tag
- 緩沖液成份20mM Tris, 150mM NaCl緩沖液(pH8.0, 含有1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose和Proclin300)
- 性狀凍干粉
- 純度> 97%
- 等電點7.1
-
應(yīng)用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白,請參見活性蛋白。 - 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價格 ¥ 1080 ¥ 2700 ¥ 5400 ¥ 16200 ¥ 40500
- 欲了解實際交易價格和更多情況,請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
序列
用法
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復(fù)凍融。2-8°C不超過一個月,-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲,損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
編號 | 適用物種:Rattus norvegicus (Rat,大鼠) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPA144Ra01 | 血管內(nèi)皮生長因子B(VEGFB)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA144Ra01 | 血管內(nèi)皮生長因子B(VEGFB)多克隆抗體 | WB; IHC; ICC; IP. |
SEA144Ra | 血管內(nèi)皮生長因子B(VEGFB)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA144Ra | 血管內(nèi)皮生長因子B(VEGFB)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
International Journal of Cardiology | Reduced microvascular density in non-ischemic myocardium of patients with recent non-ST-segment-elevation myocardial infarction. [PubMed: 22459379] |
Applied Sciences-Basel | Assessment of annexin A5 and annexin A2 levels as biomarkers for pre-eclampsia: A pilot study [pubmed:29099033] |
Journal of Endocrinological Investigation | Plasma vascular endothelial growth factor B levels are increased in patients with newly diagnosed type 2 diabetes mellitus and associated with the first phase of glucose-stimulated insulin secretion function of β-cell [10.1007/s40618-017-0677-z] |
EXCLI Journal | Plasma vascular endothelial growth factor B is elevated in non-alcoholic fatty liver disease patients and associated with blood pressure and renal dysfunction [] |
Cancer Chemother Pharmacol | Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors [34164713] |
留言咨詢